| Title |
Early development of anti-natalizumab antibodies in MS patients
|
|---|---|
| Published in |
Journal of Neurology, June 2013
|
| DOI | 10.1007/s00415-013-6991-2 |
| Pubmed ID | |
| Authors |
B. Oliver-Martos, T. Órpez-Zafra, P. Urbaneja, R. Maldonado-Sanchez, L. Leyva, O. Fernández |
| Abstract |
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the efficacy of the treatment and an increase of adverse events. A total of 134 multiple sclerosis patients were included in the trial. Anti-natalizumab antibodies were monthly detected by ELISA up to the first year of treatment and subsequently, a determination was made at 18 months. 15.7% of the patients were positive, being 7.5% transiently positive and 8.2% persistently positive. The first appearance of anti-natalizumab antibodies occurred after the first month of treatment onset in 72% of positive patients; 18% did so after the second month, and 9.7% after the third month. Antibodies were never detected for the first time after the fourth infusion. The development of anti-natalizumab antibodies occurs very early after treatment onset. This observation should be considered when standardizing the follow up of patients treated with this drug in order to minimize the risks and optimize the treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 18% |
| Student > Bachelor | 6 | 18% |
| Student > Postgraduate | 3 | 9% |
| Student > Master | 3 | 9% |
| Other | 2 | 6% |
| Other | 7 | 21% |
| Unknown | 7 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 32% |
| Agricultural and Biological Sciences | 4 | 12% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Neuroscience | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 8 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2013.
All research outputs
#4,571,231
of 22,712,476 outputs
Outputs from Journal of Neurology
#1,142
of 4,454 outputs
Outputs of similar age
#39,770
of 197,989 outputs
Outputs of similar age from Journal of Neurology
#6
of 51 outputs
Altmetric has tracked 22,712,476 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,454 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.